All In Biotech

Drug Trial Radar · NCT06488209

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

A Phase 1 Randomized, 3-Part, Placebo-Controlled, Single Ascending and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of LAD191 in Healthy Subjects and Subjects With an Autoimmune Disease

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Jul 29, 2022

Primary completion

Apr 3, 2025

Study completion Apr 3, 2025

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Jul 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.

Conditions

  • Healthy Volunteers
  • Autoimmune Disease

Interventions

  • LAD191Drug

    LAD191 SC injection.

  • PlaceboOther

    Matching placebo SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEsTime frame: Baseline up to Day 73
  2. Part 1: Number of Participants who have Dose-limiting Adverse ReactionsTime frame: Baseline up to Day 73
  3. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 73
  4. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Physical Examination FindingsTime frame: Baseline up to Day 73
  5. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Electrocardiograms (ECGs) ParametersTime frame: Baseline up to Day 73
  6. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 73
  7. Part 2 and 3: Number of Participants with Adverse Events (AEs) and Severity of AEsTime frame: Baseline up to Day 94
  8. Part 2 and 3: Number of Participants who have Dose-limiting Adverse ReactionsTime frame: Baseline up to Day 94
  9. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 94
  10. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Physical Examination FindingsTime frame: Baseline up to Day 94
  11. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in ECGs ParametersTime frame: Baseline up to Day 94
  12. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 94

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Doral Medical Research

    Miami, Florida

  • Jennifer Parish, MD

    Philadelphia, Pennsylvania

  • ICON Early Phase Services, LLC

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.